SOLID TUMORS, KRAS MUTATION; SOS1

Clinical trials for SOLID TUMORS, KRAS MUTATION; SOS1 explained in plain language.

Never miss a new study

Get alerted when new SOLID TUMORS, KRAS MUTATION; SOS1 trials appear

Sign up with your email to follow new studies for SOLID TUMORS, KRAS MUTATION; SOS1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

First-in-Human attack on KRAS cancer mutation begins

Disease control Ongoing

This is the first study in humans testing a new drug, BI 1701963, designed to block a specific cancer-driving mutation called KRAS. It is being tested alone and combined with an existing drug, trametinib, in 71 adults with advanced solid tumors where previous treatments have fail…

Matched conditions: SOLID TUMORS, KRAS MUTATION; SOS1

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

SOLID TUMORS, KRAS MUTATION; SOS1

Get alerted when new SOLID TUMORS, KRAS MUTATION; SOS1 trials appear

First-in-Human attack on KRAS cancer mutation begins